|
Hematology/Oncology Research Studies: Open for Enrollment | Date: 01/26/21 |
|---|
| NCT#/Phase: | NCT03057626 N/A |
|---|---|
| IRB#: | 2017-077 |
| Description: | Potentially eligible patients identified from ANBL00B1 will be recruited by their treating COG institution to participate in one day of clinical testing. In addition to clinical and laboratory assessments, participants will provide a blood sample and patients and parents will complete self-report quality of life and psychosocial assessments. Understanding the burden of chronic disease in survivors of high-risk neuroblastoma is critical for informing appropriate long-term care of survivors as well as for planning future trials of upfront neuroblastoma therapy |
| Inclusion: | This study will identify a large cohort of patients with high-risk neuroblastoma, all enrolled on the COG Neuroblastoma Biology study (ANBL00B1), who have survived relapse free for at least 5 years following diagnosis. |
| Enrollment Status: | Open for enrollment |
| Sponsor: | COG |
| Principal Investigator(s): | Carla Golden, MD |
| Contact(s): | Sheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611) COG CRA Office (510-428-3885 x8334) |
| Study Link: | https://clinicaltrials.gov/ct2/show/NCT03057626 |